Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Phase 1
Recruiting
- Conditions
- Lung Atypical Carcinoid TumorMetastatic Pancreatic Neuroendocrine TumorLung Typical Carcinoid Tumor
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT03879694
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Phase 2
Withdrawn
- Conditions
- Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment LevelBlasts Under 5 Percent of Peripheral Blood White CellsIDH2 Gene MutationRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Hematopoietic Cell Transplantation
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT03881735
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈCancer Institute at St Francis Hosptial, East Hills, New York, United States
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
Not Applicable
Recruiting
- Conditions
- Stage A Prostate CancerStage III Prostate CancerStage IIIB Prostate CancerStage IV Prostate CancerObesityStage C Prostate CancerStage II Prostate CancerStage IIB Prostate CancerStage IIC Prostate CancerStage IIIA Prostate Cancer
- Interventions
- Dietary Supplement: Dietary InterventionOther: Educational InterventionBehavioral: Exercise InterventionOther: Quality-of-Life AssessmentOther: Survey Administration
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03880422
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers
Not Applicable
Recruiting
- Conditions
- Current Every Day SmokerCigarette SmokerCurrent Smoker
- Interventions
- Other: Questionnaire AdministrationProcedure: Sham InterventionProcedure: Repetitive Transcranial Magnetic Stimulation
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 300
- Registration Number
- NCT03865472
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Phase 1
Withdrawn
- Conditions
- CD22 PositiveLymphoblasts 20 Percent or More of Bone Marrow Nucleated CellsRecurrent B Acute Lymphoblastic LeukemiaAllogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Peripheral Blood White CellsLymphoblasts 20 Percent or More of Peripheral Blood White CellsRefractory B Acute Lymphoblastic LeukemiaBlasts 5 Percent or More of Bone Marrow Nucleated Cells
- Interventions
- Biological: Inotuzumab OzogamicinOther: Quality-of-Life Assessment
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT03851081
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma
Not Applicable
Completed
- Conditions
- Plasma Cell Myeloma
- Interventions
- Device: FitBitOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationOther: Resistance TrainingBehavioral: STEPS to Enhance Physical Activity
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 65
- Registration Number
- NCT03793907
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity
Not Applicable
Completed
- Conditions
- Cancer SurvivorInvasive Breast Carcinoma
- Interventions
- Other: Physical ActivityOther: Questionnaire AdministrationProcedure: Repetitive Transcranial Magnetic StimulationProcedure: Sham Intervention
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03789877
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Exercise and Nutrition Education in Improving Physical Function and Quality of Life in Older Breast Cancer Survivors
Not Applicable
Terminated
- Conditions
- Anatomic Stage IIB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8ObesityPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8
- Interventions
- Other: Educational InterventionBehavioral: Exercise InterventionOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03751449
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Castration Levels of TestosteroneStage IVB Prostate Cancer AJCC v8Metastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8Castration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma in the Soft TissueProstate Carcinoma Metastatic in the BonePSA ProgressionStage IVA Prostate Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03751436
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Phase 2
Terminated
- Conditions
- Locally Advanced Digestive System Neuroendocrine CarcinomaLocally Advanced Pancreatic Neuroendocrine CarcinomaRefractory Pancreatic Neuroendocrine CarcinomaUnresectable Digestive System Neuroendocrine CarcinomaMetastatic Digestive System Neuroendocrine CarcinomaMetastatic Pancreatic Neuroendocrine CarcinomaRefractory Digestive System Neuroendocrine CarcinomaUnresectable Pancreatic Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT03736720
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈStony Brook Cancer Center, Stony Brook, New York, United States